Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan double upgrades InterContinental Hotels to 'overweight'

(Sharecast News) - InterContinental Hotels rallied on Friday after JPMorgan Cazenove double upgraded the stock to 'overweight' from 'underweight' and hiked the price target to 10,400 from 8,500p, saying it expects the narrative to turn more constructive. JPM noted the shares have underperformed materially year to date, as a function of IHG's US exposure, FX, and a softer core underlying momentum in part triggered by a weaker revenue per available room (RevPAR) across key geographies of the US, China and UK.

Going forward, with RevPAR expectations now rebased, JPM said it expects the narrative to turn more constructive, gradually pivoting towards IHG's superior earnings visibility, high free cash flow conversion, allowing for circa 5% of shares repurchased annually, and execution.

"With IHG's pipeline at 34% of its existing footprint (high end of its typical 30-35% range) and sound progress in sight on the net unite growth front as a result, we would expect IHG's valuation premium to persist, in line with US peers (solid business structurally with sound earnings visibility and margin upside, scarcity of quality alternatives within Consumer)," it said.

In the same research note, JPM said it prefers IHG and Accor - also rated 'overweight' - to Premier Inn owner Whitbread, which it has a 'neutral' rating on.

"Accor's equity story is different but also appealing, offering material re-rating potential - above-average RevPAR momentum, improved execution and capital allocation framework, disposal of Essendi well on track," it said.

"We remain on the sidelines on WTB; as a domestic play, we would expect some consumer nervousness ahead of the UK Budget (Nov 26) to weigh on sentiment, with Germany's trading momentum separately not helpful."

At 1145 BST, IHG shares were 2.7% higher at 9,008p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.